NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

癲癇發作治療市場 - 醫藥品類型·發作類型·給藥途徑·流通管道·各地區:市場規模·佔有率·展望·機會·分析 (2020-2027年)

Epileptic Seizures Treatment Market, by Drug Type, by Seizure Type, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

出版商 Coherent Market Insights 商品編碼 980023
出版日期 內容資訊 英文 204 Pages
商品交期: 2-3個工作天內
價格
癲癇發作治療市場 - 醫藥品類型·發作類型·給藥途徑·流通管道·各地區:市場規模·佔有率·展望·機會·分析 (2020-2027年) Epileptic Seizures Treatment Market, by Drug Type, by Seizure Type, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027
出版日期: 2020年12月24日內容資訊: 英文 204 Pages
簡介

癲癇病例數的增加將推動全球癲癇治療市場的增長。例如,根據2017年澳大利亞癲癇行動的一項統計調查,全世界約有5000萬人患有癲癇病,其中約80%生活在印度,巴西和中國等新興經濟體中。此外,癲癇藥物的銷售增長有望創造一個環境,​​從而導致市場增長。

本報告提供全球癲癇發作治療市場相關調查,提供市場概要,市場趨勢,影響市場的因素分析,需求分析,各市場區隔·各地區的市場分析,價格分析,並提供主要企業簡介等資訊。

目錄

第1章 調查目的·前提條件

第2章 市場展望

  • 報告的說明
    • 市場定義和範圍
  • 摘要整理
    • 市場明細:各醫藥品類型
    • 市場明細:各發作類型
    • 市場明細:各給藥途徑
    • 市場明細:各流通管道
    • 市場明細:各地區
  • 連貫機遇地圖(COM)

第3章 市場動態,法規,及趨勢分析

  • 促進因素
  • 阻礙因素
  • 市場機會
  • 影響分析
  • 流行病學
  • 法規方案
  • 償付方案
  • 新產品的銷售/核准
  • 主要的發展
  • 政府的積極推動和資金
  • 合作和合作關係
  • PEST分析

第4章 全球癲癇發作治療市場:冠狀病毒(Covid-19)疫情的影響

  • COVID19中的市場情況
  • 整體影響
  • 供給面和需求面分析

第5章 全球癲癇發作治療市場:各醫藥品類型

  • 簡介
  • 第1代
  • 第2代
  • 第3代

第6章 全球癲癇發作治療市場:各發作類型

  • 簡介
  • 部分性發作
  • 整體發作
  • 無法分類的發作

第7章 全球癲癇發作治療市場:各給藥途徑

  • 簡介
  • 口服/口腔
  • 經鼻
  • 直腸
  • 非口服

第8章 全球癲癇發作治療市場:各銷售管道

  • 簡介
  • 醫院藥局
  • 零售藥局
  • 線上藥局

第9章 全球癲癇發作治療市場:各地區

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東
  • 非洲

第10章 競爭情形

  • 企業簡介
    • Novartis AG
    • GlaxoSmithKline Plc
    • Johnson & Johnson Service, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Pfizer, Inc.
    • Sanofi SA
    • Mylan NV
    • Bausch Health Companies Inc.
    • UCB SA
    • Eisai Co. Ltd.
    • Abbott Laboratories
    • Sumitomo Dainippon Pharma Co., Ltd.
    • GW Pharmaceuticals Plc
    • Marinus Pharmaceuticals, Inc.
    • H. Lundbeck A/S
    • Takeda Pharmaceutical Co., Ltd.

第11章 章節

目錄

Title:
Epileptic Seizures Treatment Market, by Drug Type (First Generation, Second Generation, and Third Generation), by Seizure Type (Partial Seizures, Generalized Seizures, and Unclassified Seizures), by Route of Administration (Oral/Buccal, Nasal, Rectal, and Parenteral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027.

Epilepsy is a chronic disorder that causes unprovoked and recurrent seizures. A seizure is a sudden rush of electrical activity in the brain. Epilepsy is associated with disrupted activities in the brain called seizures, which affects the central nervous system. Epilepsy is categorized into generalized seizures and partial seizures based on the areas affected in the brain. An increasing number of epilepsy cases is expected to drive growth of the global epileptic seizures treatment market. For instance, according to the study by Epilepsy Action Australia statistics in 2017, around 50 million people globally had epilepsy with around 80% of the people living in emerging economies such as India, Brazil, and China.

Moreover, increasing launches of drugs for treatment of epilepsy is expected to create conducive environment for the market growth. For instance, in 2016, UCB Pharma Limited received the U.S. FDA approval for Briviact, for the treatment of patients with partial onset of seizures. Moreover, Mylan launched generic, Felbatol tablets for the treatment of epileptic seizures, in the U.S. after receiving approval from the U.S. Food & Drug Administration in 2016. These factors are expected to boost the market growth over the forecast period.

Market Dynamics

The increasing prevalence of epilepsy in adults and children, across the globe is expected to drive growth of the epileptic seizures treatment market during the forecast period. According to the WHO, around one-third of children with epilepsy can be assigned to a specific epilepsy syndrome, as defined by the most recently proposed system for organization of epilepsy syndrome. According to the Society of Neuroscience, in 2015, epilepsy affected around 10.5 million children worldwide, and the types and severity of the disorder varied significantly. Moreover, according to the American Academy of Pediatrics data published in April 2017, epilepsy affects 0.5% to 1% of children globally, and is the most frequently occurring chronic neurologic condition in childhood.

However, non-conventional anti-epileptic treatments and non-pharmacological approaches can potentially help in reduction of seizures or anti-epileptic drug toxicity. For instance, there has been increasing preference for alternative therapy for epilepsy such as corticosteroids, immunoglobulins, melatonin, and vitamins for treating children. Other than supplemental therapy, there are certain techniques that can help reduce epileptic seizures such as avoidance technique, which involves avoiding activities that can induce a seizure such as flickering lights, listening to specific type or piece of music, eating, reading, and immersion in hot water, chess playing, or brushing hair. Thus, these factors are expected to restrain the epileptic seizures treatment market growth. Other non-pharmacological treatments for epilepsy in children include herbal medicine, homeopathy, yoga, aromatherapy, and coping strategies.

Key features of the study:

  • This report provides in-depth analysis of the global epileptic seizures treatment market, market size (US$ Bn), and compound annual growth rate (CAGR (%)) for the forecast period: 2020-2027, considering 2019 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global epileptic seizures treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Novartis AG, GlaxoSmithKline Plc, Johnson & Johnson Service, Inc., Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Sanofi S.A., Mylan N.V., Bausch Health Companies Inc., UCB S.A., Eisai Co. Ltd., Abbott Laboratories, Sumitomo Dainippon Pharma Co., Ltd., GW Pharmaceuticals Plc, Marinus Pharmaceuticals, Inc., H. Lundbeck A/S, and Takeda Pharmaceutical Co., Ltd.
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global epileptic seizures treatment market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for epileptic seizures treatment market, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:

  • Global Epileptic Seizures Treatment Market, By Drug Type:
    • First Generation
    • Second Generation
    • Third Generation
  • Global Epileptic Seizures Treatment Market, By Seizure Type:
    • Partial Seizures
    • Generalized Seizures
    • Unclassified Seizures
  • Global Epileptic Seizures Treatment Market, By Route of Administration:
    • Oral/Buccal
    • Nasal
    • Rectal
    • Parenteral
  • Global Epileptic Seizures Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Epileptic Seizures Treatment Market, By Region:
    • North America
      • By Country:
    • U.S.
    • Canada
      • By Drug Type:
    • First Generation
    • Second Generation
    • Third Generation
      • By Seizure Type:
    • Partial Seizures
    • Generalized Seizures
    • Unclassified Seizures
      • By Route of Administration:
    • Oral/Buccal
    • Nasal
    • Rectal
    • Parenteral
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Europe
      • By Country:
    • U.K.
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • Rest of Europe
      • By Drug Type:
    • First Generation
    • Second Generation
    • Third Generation
      • By Seizure Type:
    • Partial Seizures
    • Generalized Seizures
    • Unclassified Seizures
      • By Route of Administration:
    • Oral/Buccal
    • Nasal
    • Rectal
    • Parenteral
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Asia Pacific
      • By Country:
    • Australia
    • India
    • China
    • Japan
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
      • By Drug Type:
    • First Generation
    • Second Generation
    • Third Generation
      • By Seizure Type:
    • Partial Seizures
    • Generalized Seizures
    • Unclassified Seizures
      • By Route of Administration:
    • Oral/Buccal
    • Nasal
    • Rectal
    • Parenteral
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Latin America
      • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
      • By Drug Type:
    • First Generation
    • Second Generation
    • Third Generation
      • By Seizure Type:
    • Partial Seizures
    • Generalized Seizures
    • Unclassified Seizures
      • By Route of Administration:
    • Oral/Buccal
    • Nasal
    • Rectal
    • Parenteral
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Middle East
      • By Country:
    • GCC
    • Israel
    • Rest of Middle East
      • By Drug Type:
    • First Generation
    • Second Generation
    • Third Generation
      • By Seizure Type:
    • Partial Seizures
    • Generalized Seizures
    • Unclassified Seizures
      • By Route of Administration:
    • Oral/Buccal
    • Nasal
    • Rectal
    • Parenteral
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Africa
      • By Country/Region:
    • South Africa
    • Central Africa
    • North Africa
      • By Drug Type:
    • First Generation
    • Second Generation
    • Third Generation
      • By Seizure Type:
    • Partial Seizures
    • Generalized Seizures
    • Unclassified Seizures
      • By Route of Administration:
    • Oral/Buccal
    • Nasal
    • Rectal
    • Parenteral
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Company Profiles
    • Novartis AG *
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • GlaxoSmithKline Plc
    • Johnson & Johnson Service, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Pfizer, Inc.
    • Sanofi S.A.
    • Mylan N.V.
    • Bausch Health Companies Inc.
    • UCB S.A
    • Eisai Co. Ltd.
    • Abbott Laboratories
    • Sumitomo Dainippon Pharma Co., Ltd.
    • GW Pharmaceuticals Plc
    • Marinus Pharmaceuticals, Inc.
    • H. Lundbeck A/S
    • Takeda Pharmaceutical Co., Ltd.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Type
    • Market Snippet, By Seizure Type
    • Market Snippet, By Route of Administration
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Drivers
  • Restraints
  • Market Opportunities
  • Impact Analysis
  • Epidemiology
  • Regulatory Scenario
  • Reimbursement Scenario
  • New Product Launches/Approvals
  • Key Developments
  • Government Initiatives and Funding
  • Collaborations & Partnerships
  • PEST Analysis

4. Global Epileptic Seizures Treatment Market - Impact of Coronavirus (Covid-19) Pandemic

  • During-COVID 19 Market Situation
  • Overall Impact
  • Supply Side And Demand Side Analysis

5. Global Epileptic Seizures Treatment Market , By Drug Type, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • First Generation
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Second Generation
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Third Generation
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

6. Global Epileptic Seizures Treatment Market, By Seizure Type, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Partial Seizures
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Generalized Seizures
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Unclassified Seizures
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

7. Global Epileptic Seizures Treatment Market, By Route of Administration, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Oral/Buccal
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Nasal
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Rectal
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Parenteral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

8. Global Epileptic Seizures Treatment Market, By Distribution Channel, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

9. Global Epileptic Seizures Treatment Market, By Region, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, By Region, 2017 - 2027
    • Regional Trends
  • North America
    • Market Size and Forecast, By Drug Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Seizure Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Drug Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Seizure Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Seizure Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast, By Drug Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Seizure Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Middle East
    • Market Size and Forecast, By Drug Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Seizure Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Drug Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Seizure Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country/Region, 2016 - 2027, (US$ Million)
    • North Africa
    • Central Africa
    • South Africa

10. Competitive Landscape

  • Company Profiles
    • Novartis AG
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • GlaxoSmithKline Plc
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Johnson & Johnson Service, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Teva Pharmaceutical Industries Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Pfizer, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Sanofi S.A.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Mylan N.V.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Bausch Health Companies Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • UCB S.A
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Eisai Co. Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Abbott Laboratories
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Sumitomo Dainippon Pharma Co., Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • GW Pharmaceuticals Plc
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Marinus Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • H. Lundbeck A/S
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Takeda Pharmaceutical Co., Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies

11. Section

  • References
  • Research Methodology
  • About us and Sales Contact